EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term use of hormonal contraceptives: Thromboembolic and metabolic repercussions in clinical practice

Júlia Maurício Barreto de Fontes, Eduarda Lessa Lopes Barbosa, Lais Carvalho Ferreira Santos, Ariane Francisca Batista Costa

International Health Sciences Review · 29.03.2026 · 2 (2)

DOI: 10.70164/ihsr.v2i2.149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Health Sciences Review, online erschienen am 29.03.2026. Verfasst von Júlia Maurício Barreto de Fontes und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hormonal contraceptives remain one of the most widely used reversible methods in women’s health, and their long-term safety continues to be central to clinical decision-making. This narrative literature review examined evidence from PubMed, SciELO, the Cochrane Library, and major eligibility guidelines from the CDC, WHO, and FSRH, with emphasis on combined hormonal contraceptives, venous thromboembolism, arterial events, glucose metabolism, and lipid changes. The evidence consistently shows that combined hormonal contraceptives increase venous thromboembolism risk compared with nonuse, largely through estrogen-mediated hepatic and hemostatic effects, with risk varying according to estrogen dose and progestogen type. Levonorgestrel-containing formulations generally show the most favorable venous safety profile among combined oral contraceptives, whereas desogestrel, gestodene, and drospirenone are associated with higher relative risk. Arterial events such as ischemic stroke and myocardial infarction remain uncommon in reproductive-age women, but their incidence rises with smoking, age, hypertension, migraine with aura, and higher estrogen exposure. Metabolic effects are usually modest in healthy users, yet triglycerides and cholesterol fractions may worsen in susceptible women, particularly during prolonged exposure or in the presence of baseline cardiometabolic risk. In clinical practice, contraceptive choice should be individualized through structured thrombotic and metabolic screening, with preference for lower-risk or progestin-only options when baseline cardiovascular vulnerability is present

Zitieren

APA

Fontes, J. M. B. D., Barbosa, E. L. L., Santos, L. C. F., & Costa, A. F. B. (2026). Long-term use of hormonal contraceptives: Thromboembolic and metabolic repercussions in clinical practice. International Health Sciences Review, 2(2). https://doi.org/10.70164/ihsr.v2i2.149

Vancouver

Fontes JMBD, Barbosa ELL, Santos LCF, Costa AFB. Long-term use of hormonal contraceptives: Thromboembolic and metabolic repercussions in clinical practice. International Health Sciences Review. 2026;2(2). doi:10.70164/ihsr.v2i2.149

BibTeX
@article{Fontes2026,
  author = {Fontes, Júlia Maurício Barreto de and Barbosa, Eduarda Lessa Lopes and Santos, Lais Carvalho Ferreira and Costa, Ariane Francisca Batista},
  title = {Long-term use of hormonal contraceptives: Thromboembolic and metabolic repercussions in clinical practice},
  journal = {International Health Sciences Review},
  year = {2026},
  volume = {2},
  number = {2},
  doi = {10.70164/ihsr.v2i2.149}
}
Kostenlos starten →